GSK放棄艾滋病藥品部門上市計劃

GlaxoSmithKline has dropped plans to sell part of its HIV drugs unit and promised to hold its dividend steady for the next three years as the struggling UK pharmaceuticals group set out its strategy to revive growth.

葛蘭素史克(GlaxoSmithKline，簡稱GSK)已放棄了轉讓部分艾滋病(HIV)藥物部門的計劃，並承諾要在今後三年內保證其穩定分紅。這家深陷困境的英國製藥集團正要着手實施其重獲增長的戰略。

The u-turn on a proposed multibillion-pound initial public offering of the ViiV Healthcare unit was the biggest surprise in a closely-watched presentation by Sir Andrew Witty, chief executive, aimed at shoring up investor confidence in the company and his leadership.

這個擬議中的ViiV Healthcare部門的首次公開招股(IPO)交易規模達數十億英鎊。安德魯•維迪爵士(Sir Andrew Witty)的講話中最令人震驚的一幕，就是該交易出現180度大轉彎。這一講話旨在提升投資者對GSK前景及安德魯爵士領導力的信心，廣受密切關注。

Sir Andrew floated the idea of a flotation for ViiV last year as a way to unlock value for GSK shareholders in what would have been among the biggest UK IPOs on record. He said on Wednesday it made more sense to keep the business because its growth prospects were stronger than anticipated.

安德魯爵士去年提出了將ViiV部門掛牌上市的想法，並把它作爲GSK股東解放其股票價值的途徑。該交易原本可能成爲英國有記錄以來規模最大的IPO之一。週三，安德魯爵士表示，由於該部門增長前景強於預期，將該部門留在GSK集團內更有意義。

The decision came as he set out his plans for turning GSK round after a period of falling sales for its crucial respiratory drugs in the US and a bruising corruption scandal in China.

公佈這一決策之際，安德魯爵士正着手實施重振GSK的計劃。此前一段時期內，該公司不僅至關重要的呼吸系統藥物在美國銷量不斷下滑，還在中國捲入了令它灰頭土臉的腐敗醜聞。

Earnings were forecast to drop by a high-teens percentage this year — more than analysts had expected — but Sir Andrew said growth would return next year and rise by a compound annual rate in the mid-to-high single digits between 2016 and 2020.

今年該公司盈利的下跌幅度預計會在16%到19%之間，高於分析師的預期。不過，安德魯爵士表示明年該公司就會恢復增長，2016年到2020年該公司複合年增長率將在5%到9%之間。